Results 121 to 130 of about 140,144 (311)

Metastatic Cutaneous Adnexal Carcinoma of the Head and Neck With Durable Response to an Aromatase Inhibitor Combined With a Cyclin‐Dependent Kinase 4/6 Inhibitor

Head &Neck, Volume 48, Issue 7, Page E70-E75, July 2026.
ABSTRACT Background Cutaneous adnexal carcinomas are a very rare group of cancers arising from appendageal structures of the skin. More than half occur in the head and neck region. No standard treatments exist for metastatic disease. Methods A 48‐year‐old postmenopausal female presented with an enlarging scalp lesion.
Nilesh Kapoor, Manasa Narasimman, Travis Vandergriff, Amy L. Jones   +3 more
wiley   +1 more source

Severe neutropenia in a breastfed infant: a case report and discussion of the differential diagnosis

, 2018
Leonie van den Broek,1 Jutte van der Werff-ten Bosch,2 Pieter-Jan Cortoos,3 Susanne van Steijn,1 Machiel van den Akker1,21Department of Pediatrics, Queen Paola Children’s Hospital, Antwerp, Belgium; 2Department of Pediatric Hematology Oncology,
Cortoos P, van den Akker M, van Steijn S, van der Werff ten-Bosch J, van den Broek L   +4 more
core  

Management of febrile neutropenia [PDF]

, 2007
Neutropenia is a severe and very frequent complication of anticancer chemotherapy. Febrile neutropenia is a serious consequence of neutropenia caused by cancer chemotherapy, often leads to hospitalization, need of parenteral antibiotics and lethal end ...
Vachek, Jan
core  

Olanzapine-induced neutropenia

, 2015
Olanzapine-induced neutropenia is a rare adverse effect that is currently poorly described in literature. Although neutropenia is a known adverse effect of clozapine, it has been associated with the use of other antipsychotic medications like olanzapine.
Hank Lai, Priscilla Vu, Kirti Malhotra, Lawrence R. Faziola, Danielle H. Wang   +4 more
core   +1 more source

Treatment‐Related Adverse Events and Health‐Related Quality of Life Associated With Immune Checkpoint Inhibitor Treatment for Mucosal Head and Neck Squamous Cell Carcinoma: A Scoping Review

Head &Neck, EarlyView.
ABSTRACT Background Supportive care needs of patients receiving immune checkpoint inhibitors (ICIs) for head and neck squamous cell carcinoma (HNSCC) are ill‐defined. Hence, known treatment‐related adverse events (TRAEs) and health‐related quality of life (HRQoL) associated with ICI treatment for HNSCC were examined to inform future supportive care ...
N. D. O'Donnell, E. C. Ward, L. R. Wishart, R. Perera, C. Barrett, K. A. Edmiston, E. Mitchell, A. Pigott, R. Pitt, K. Russell, B. A. Chan, R. Ladwa   +11 more
wiley   +1 more source

New developments in the treatment of chemotherapy-induced neutropenia: focus on balugrastim

, 2016
Michele Ghidini,1 Jens Claus Hahne,2 Francesco Trevisani,3 Stefano Panni,1 Margherita Ratti,1 Laura Toppo,1 Gianluca Tomasello1 1Medical Department, Division of Oncology, ASST di Cremona, Ospedale di Cremona, Cremona, Italy; 2Division of Molecular ...
Panni S, Toppo L, Ghidini M, Hahne JC, Trevisani F, Tomasello G, Ratti M   +6 more
core  

Neutropenia febril

, 2023
não temNeutropenia febril (NF) é uma complicação, geralmente, associada à quimioterapia, com altas taxas de mortalidade, aproximadamente, 20% (Choi et al., 2022).
Lima, Jasmine Paula Rodrigues de
core  

Cyclical Neutropenia [PDF]

Proceedings of the Royal Society of Medicine, 1968
D I, Evans, A, Holzel
openaire   +2 more sources

Efficacy and Safety Profile of a Rituximab, Methotrexate, and Thiotepa‐Based Regimen in Newly Diagnosed Primary CNS Lymphoma

International Journal of Cancer, EarlyView.
Primary central nervous system diffuse large B‐cell lymphoma (PCNS‐DLBCL) lacks an optimal first‐line induction strategy, particularly for older patients and those ineligible for intensive consolidation. In this retrospective cohort of 36 newly diagnosed patients, the rituximab + methotrexate + thiotepa (RMT) regimen as first‐line induction achieved ...
Haotian Wang, Jia Li, Luming Cao, Ying Zhang, Xin Wan, Xingtong Wang, Yangzhi Zhao, Zhaoxia Li, Chengqian Chen, Yang Song, Ou Bai   +10 more
wiley   +1 more source

Association between neutropenia and efficacy in patients with refractory mCRC receiving trifluridine/tipiracil + bevacizumab: post hoc analysis of the SUNLIGHT trial

ESMO Gastrointestinal Oncology
Background: The efficacy of trifluridine/tipiracil (FTD/TPI) + bevacizumab compared with FTD/TPI for the treatment of refractory metastatic colorectal cancer (mCRC) was demonstrated in the SUNLIGHT trial.
G.W. Prager, E. Elez, M. Fakih, F. Ciardiello, E. Van Cutsem, L. Roby, W. Yao, E. Choucair, J. Taieb   +8 more
doaj   +1 more source